rising stars

Rice Alliance announces 4 most promising energy tech companies at OTC

Another Offshore Technology Conference, another Venture Day hosted by the Rice Alliance for Technology and Entrepreneurship. Photo by Zukiman Mohamad/Pexels

Fourteen companies pitched at the Rice Alliance for Technology and Entrepreneurship's Energy Venture Day at the 2021 Offshore Technology Conference, and virtual attendees voted on the companies they think are the most promising.

The companies, which hailed from three countries, again pitched virtually. Last year's venture day was also hosted virtually. The event's judging panel usually names 10 of the most promising companies at the event, however, just like last year, Rice Alliance put the power into the people viewing the pitches online.

Here are the four most promising energy tech companies that pitched at the annual OTC event.

American Hydrogen

Image via amhydrogen.com

Based in Tulsa, Oklahoma, American Hydrogen offers a fully integrated, end-to-end implementation solutions for hydrogen generation, storage, and distribution facilities.

"With roots in traditional energy, the American Hydrogen management team consists of senior oil and gas professionals who have spend decades developing infrastructure in prominent energy hubs across the United States. Through this field experience our team can furnish reliable and proven execution for an emerging clean technology market," per the company's website.

Alabastron Technologies

Image via alabastron.net

Houston-based Alabastron Technologies has developed a sensor that can detect organic and inorganic deposition in pipelines before any actual deposits form.

"Our service is a real-time closed-loop sensing, measurement and control strategy that remotely monitors oil production and the tendency of flow-restricting-substances or depositions prior to actual deposition," reads the company's website.

Applied Bioplastics

Photo via Getty Images

Applied Bioplastics, based in Austin, is commercializing an alternative to plastic by combining it plant fiber — operating with a carbon footprint 30 percent smaller than traditional plastic.

"Our products reduce petroleum dependency, pollution, and habitat destruction. Through our supply chains, we support eco-friendly agriculture in developing countries," according to the website.

DataSeer

Photo via dataseer.digital

Houston-based DataSeer is a cloud-based software application uses artificial intelligence to automatically detect, label and extract information from engineering data. The technology improves its customer's quality control and quality assurance of data extraction at scale.

"DataSeer was built in close collaboration with users at some of the largest engineering firms in the world, who we are proud to call our customers," the website reads.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted